Congestive Heart FailureNCT02489370
CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial
A study testing Home telemonitoring in people with Congestive Heart Failure, run by University Hospital of North Norway at 1 site in Norway.
Trial summary
Providing patients with chronic heart failure (CHF) access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Congestive Heart Failure
- What is being tested?
- Home telemonitoring
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteNorway
- Study dates
- Oct 2014to Dec 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Presence of CHF signs and symptoms such as dyspnoea and peripheral or pulmonary oedema requiring diuretic administration (New York Heart Association [NYHA] functional class II-IV); and ejection fraction (EF) under 40% combined or not with a left ventricular filling pattern supporting the presence of diastolic dysfunction, according to the American College of Cardiology/American Heart Association Guidelines for chronic heart failure.
Who cannot join
- Severe psychiatric disturbance diagnosed by DSM-IV-TR criteria. Any disability that may prevent the subject from completing the informed consent form or other study requirements.
- Medication or drug dependency or abuse (except for nicotine). Inability to handle the technological devices included in the study, for some other reason.
Trial locations and contacts
1 site in 1 country.
Norway1 site, 1 recruiting
- Recruiting
University Hospital of North Norway
Tromsø, Troms, N-9038
J. Artur Serrano, PhD, +4796683435, jarturserrano@gmail.com
Ragnhild Jonassen, Nurse, +4777626914, ragnhild.jonassen@unn.no
About this study
Providing patients with chronic heart failure (CHF) access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. Remote monitoring of patients with chronic heart failure can reduce pressure on resources, particularly for conditions like chronic heart failure, which exert a large burden on health services. These are conclusions of the Cochrane Systematic Review from 2010.
In Norway the costs for treatment of chronic heart failure are vast, both concerning hospital treatment, daily use of medication over years, and loss of quality of life for patients and their family caregivers. Generally there is little knowledge about what is gained for the billions used. In Norway no telemonitoring services are established and hence no investigations have yet been published. Thus it seems that current evidence of effectiveness and quality is insufficient to recommend usage. The structure and funding streams in Norwegian health services are different from other countries and the conventional services that the intervention has been compared to in previous studies, are most likely heterogeneous. It is thus important to investigate Norwegian conditions.
Read more
Advanced telemonitoring technology with electronic transfer of physiological data such as blood pressure and weight is currently being used in research and established routine services in several countries in Europe, amongst them the Netherlands, Germany and the United Kingdom.
The proposed project intends to introduce such a strategy as an avenue for exploring promising new services that would not otherwise be available in Norway. The service consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the University Hospital of North Norway (UNN); and monitor the values by a trained nurse at the Heart polyclinic.
The primary objective of this study is thus to explore whether, as compared to current care from the Heart Polyclinic, the introduction of home telemonitoring will reduce hospital readmissions and will, in addition, be cost-effective. This is in line with current directions of European telemonitoring programmes for patients with chronic heart failure. This result may define if the telemonitoring of heart failure patients is feasible for Norway or not at all.
Read the detailed description
All data collected by the equipment placed at the patient's home will be directly and securely transferred to the Heart polyclinic of the University Hospital of North Norway (UNN). All data is anonymous as explained below, only the weight and the codes with the answers to the questionnaire are send.
Each day a nurse is assigned as responsible for the heart remote monitoring system. The nurse in charge must read the heart remote monitoring email in the morning every day, seven days a week. If an alert email has been received, then the nurse logs into the system's dashboard and reads the data displayed there for that patient. Then the nurse will try to phone the patient to clarify the situation. Until this moment the procedure protocol differs from the ordinary routines as the notification of a case is usually raised by a phone call from the patient or a hospitalisation. But from this moment on, the procedure protocol is the same as for all patients treated by the Heart polyclinic, i.e. if the nurse evaluates the situation to need a further follow-up, then the nurse contacts the patient's general practitioner (GP) by phone (as said this is procedure as usual). The hospital's Heart polyclinic has the same responsibility for the treatment of the patients, both in the intervention arm and the control arm.
Each one of the patients assigned to the intervention arm will be following this procedure during 6 months. For the patients assigned to the control arm they will receive treatment as usual also during a period of 6 months. Data stored in the system is anonymised. All patients are uniquely identified by a number, the Unique Identifier (UID), in the system, the connection between the UID and the real identity being only stored in a file in a secured personal computer unconnected from any network, staying in an office at the heart polyclinic. Once a week, the UIDs' file stored in the study personal computer at the Heart polyclinic is transferred to a hardware protected pen drive. The pen drive in then placed in another building at the UNN. This procedure is of the responsibility of the UNN's department for "E-health and information and communications technology (ICT)". In this way only two copies of the file are stored in separate buildings. No reference to the study name is mentioned in this file.
As a pilot study, a prototype of the platform was built. It consisted of a wireless weight scale and also a blood pressure meter prepared to send the values through the home Wi-Fi network to a connected portable computer. The portable computer could then send the encrypted measurements to a server at UNN.
After the first two months of pilot testing, the patient was satisfied with the usability of the solution and the reliability of the service was proven.
The platform deployed and tested in the pilot study has been extended to include functionalities for multiple patients. A dashboard showing all the measurements received (unidentified) has been developed for the polyclinic and used by the responsible clinician (the nurse on daily duty). This data is unidentified and consists of a registration of blood pressure and weight, the encoded answers to the questionnaire attached (example: Q3A2 means that question 3 got the answer 2 in the questionnaire). The responsible nurse at the Heart Polyclinic has access to the dashboard. When a situation requiring the nurse intervention arises, the system sends an alerting email to a pre-defined address (usually the nurse's email account as it will be done in this study).
The design of the randomized controlled trial (RCT) Power analysis The inclusion of 40 patients is based upon the total number of new patients served by the polyclinic per year during the 2 last years. For this study a sample size was calculated based on a readmission rate of 70% of the patients per year on average with a standard deviation of 20pp (percentage points). The values are adequate, based on patients who have received treatment within the Heart Polyclinic and also replicating the study by Antonicelli, published in the Journal of telemedicine and Telecare "Impact of telemonitoring at home on the management of elderly patients with congestive heart failure" in 2008.
It was assumed by the clinical team that a 1/3 reduction on the rate of readmissions (down to 47%) would be clinically relevant as the margin of superiority for the intervention. To have 95% certainty (power) that a test at 0.05 level of significance would find a statistically significant difference between the means, the study would include a minimum of 20 patients in each group.
The planned RCT The telemonitoring service will be offered to all patients admitted at UNN's Heart Polyclinic, satisfying the inclusion criteria. The study comprises an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.
Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made.
Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
The study calendar is shown below. Recruiting period: 14 months Follow-up period: 6 months Number of patients: 40
Randomization: will be performed using sequentially numbered sealed opaque envelopes
Blinding: independent outcome assessors and data analysts are blinded to which group the patient has been assigned to (patients are not blinded due to the nature of the intervention).
Challenges and opportunities Qualitative research with semi structured interviews. Patients in the intervention group and health care professionals will be asked to state their opinion of the service. The research team will also observe patients' interactions with the system after the 6 months of the study. A qualitative summary and thematic analysis of significant features of opinions and actions will be connected to best practices. The purpose is to be able to understand how best practices can be developed in the Northern Norwegian context, and describe their mechanisms. The innovation intention is to adjust the services as they develop, by considering the identified additional conditions for future development.
Ethics and privacy With recent events and advances in information technology and the Internet, confidentiality regarding handling of patient private data has become a critical aspect of a study design as privacy is a fundamental right in the public healthcare domain. In this project confidentiality of private health information will be ensured according to the Health Personnel Act § 21, helsepersonelloven § 21, and described in LOV2001-05-18 nr.24 (Helse- og omsorgsdepartementet, 2001). All private personal data will be de-identified: every unique identifying number, characteristic, or code identifiers of the individual or of relatives, employers, or household members of the individual will be removed so that the information can be used alone or in combination with other information. The resulting data will be analysed by a statistician to ensure that no individually identifiable health information remains. The consent of participants will be required by means of providing a letter of informed consent to be signed.
- Conditions
- Congestive Heart Failure
- Being tested
- Home telemonitoring
- Keywords
- home care, telecare, telehealth, telemonitoring, chronic heart failure, randomized controlled trial, Congestive Heart Failure, telemedicine
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Home telemonitoringDevice
Also called Telecare, Telehealth
The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
| Study group | Role | What they receive |
|---|---|---|
| Telemonitoring (intervention) | Experimental | an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.
Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made. Receives: Device: Home telemonitoring |
| Usual care (control) | No intervention | Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart failure related hospital readmissions
Calculated as the proportion of patients readmitted to hospital at least once during the period of follow-up
Measured: Intervention period (6 months)
Additional costs/savings resulting from the service
Defined as the difference in the costs of medical care during the study, identified through a cost analysis, between the intervention and control arms
Measured: 6 months
Secondary outcomes (2)
Length of stay
Defined as the length of stay per hospitalization
Measured: 6 months
Assessment of Quality of Life
Based on the Minnesota Living with Heart Failure questionnaire (MLWHF)
Measured: At baseline and end of study (6 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2015 (estimated)
- Study startOct 2014
- Primary completionJun 2016 (estimated)
- Study completionDec 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Congestive Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital of North Norway
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Artur Serrano, University Hospital of North Norway
- Investigators
- J. Artur Serrano, PhD, Principal investigator, Senior Research Scientist, Norwegian Centre for Telemedicine, University Hospital of North NorwayPaal Tande, MD, Study director, Leader Cardiology Department, University Hospital of North NorwayMarina Nilsen, Nurse, Study chair, Leader Heart Polyclinic, University Hospital of North Norway
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02489370
- Sponsor's protocol ID
- 2013/356/REK nord
- Status last verified
- Jul 2015
- First submitted
- 25 Jun 2015
- Last updated
- 3 Jul 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial
- ClinicalTrials.gov ID
- NCT02489370
- Acronym / sponsor ID
- 2013/356/REK nord
- Conditions
- Congestive Heart Failure
- Keywords
- home care, telecare, telehealth, telemonitoring, chronic heart failure, randomized controlled trial, Congestive Heart Failure, telemedicine
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University Hospital of North NorwayUniversity, hospital or other
- Study start
- Oct 2014
- Primary completion
- Jun 2016 (estimated)
- Study completion
- Dec 2016 (estimated)
- First posted
- 3 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Providing patients with chronic heart failure (CHF) access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. Remote monitoring of patients with chronic heart failure can reduce pressure on resources, particularly for conditions like chronic heart failure, which exert a large burden on health services. These are conclusions of the Cochrane Systematic Review from 2010.
In Norway the costs for treatment of chronic heart failure are vast, both concerning hospital treatment, daily use of medication over years, and loss of quality of life for patients and their family caregivers. Generally there is little knowledge about what is gained for the billions used. In Norway no telemonitoring services are established and hence no investigations have yet been published. Thus it seems that current evidence of effectiveness and quality is insufficient to recommend usage. The structure and funding streams in Norwegian health services are different from other countries and the conventional services that the intervention has been compared to in previous studies, are most likely heterogeneous. It is thus important to investigate Norwegian conditions.
Advanced telemonitoring technology with electronic transfer of physiological data such as blood pressure and weight is currently being used in research and established routine services in several countries in Europe, amongst them the Netherlands, Germany and the United Kingdom.
The proposed project intends to introduce such a strategy as an avenue for exploring promising new services that would not otherwise be available in Norway. The service consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the University Hospital of North Norway (UNN); and monitor the values by a trained nurse at the Heart polyclinic.
The primary objective of this study is thus to explore whether, as compared to current care from the Heart Polyclinic, the introduction of home telemonitoring will reduce hospital readmissions and will, in addition, be cost-effective. This is in line with current directions of European telemonitoring programmes for patients with chronic heart failure. This result may define if the telemonitoring of heart failure patients is feasible for Norway or not at all.
Detailed description
All data collected by the equipment placed at the patient's home will be directly and securely transferred to the Heart polyclinic of the University Hospital of North Norway (UNN). All data is anonymous as explained below, only the weight and the codes with the answers to the questionnaire are send.
Each day a nurse is assigned as responsible for the heart remote monitoring system. The nurse in charge must read the heart remote monitoring email in the morning every day, seven days a week. If an alert email has been received, then the nurse logs into the system's dashboard and reads the data displayed there for that patient. Then the nurse will try to phone the patient to clarify the situation. Until this moment the procedure protocol differs from the ordinary routines as the notification of a case is usually raised by a phone call from the patient or a hospitalisation. But from this moment on, the procedure protocol is the same as for all patients treated by the Heart polyclinic, i.e. if the nurse evaluates the situation to need a further follow-up, then the nurse contacts the patient's general practitioner (GP) by phone (as said this is procedure as usual). The hospital's Heart polyclinic has the same responsibility for the treatment of the patients, both in the intervention arm and the control arm.
Each one of the patients assigned to the intervention arm will be following this procedure during 6 months. For the patients assigned to the control arm they will receive treatment as usual also during a period of 6 months. Data stored in the system is anonymised. All patients are uniquely identified by a number, the Unique Identifier (UID), in the system, the connection between the UID and the real identity being only stored in a file in a secured personal computer unconnected from any network, staying in an office at the heart polyclinic. Once a week, the UIDs' file stored in the study personal computer at the Heart polyclinic is transferred to a hardware protected pen drive. The pen drive in then placed in another building at the UNN. This procedure is of the responsibility of the UNN's department for "E-health and information and communications technology (ICT)". In this way only two copies of the file are stored in separate buildings. No reference to the study name is mentioned in this file.
As a pilot study, a prototype of the platform was built. It consisted of a wireless weight scale and also a blood pressure meter prepared to send the values through the home Wi-Fi network to a connected portable computer. The portable computer could then send the encrypted measurements to a server at UNN.
After the first two months of pilot testing, the patient was satisfied with the usability of the solution and the reliability of the service was proven.
The platform deployed and tested in the pilot study has been extended to include functionalities for multiple patients. A dashboard showing all the measurements received (unidentified) has been developed for the polyclinic and used by the responsible clinician (the nurse on daily duty). This data is unidentified and consists of a registration of blood pressure and weight, the encoded answers to the questionnaire attached (example: Q3A2 means that question 3 got the answer 2 in the questionnaire). The responsible nurse at the Heart Polyclinic has access to the dashboard. When a situation requiring the nurse intervention arises, the system sends an alerting email to a pre-defined address (usually the nurse's email account as it will be done in this study).
The design of the randomized controlled trial (RCT) Power analysis The inclusion of 40 patients is based upon the total number of new patients served by the polyclinic per year during the 2 last years. For this study a sample size was calculated based on a readmission rate of 70% of the patients per year on average with a standard deviation of 20pp (percentage points). The values are adequate, based on patients who have received treatment within the Heart Polyclinic and also replicating the study by Antonicelli, published in the Journal of telemedicine and Telecare "Impact of telemonitoring at home on the management of elderly patients with congestive heart failure" in 2008.
It was assumed by the clinical team that a 1/3 reduction on the rate of readmissions (down to 47%) would be clinically relevant as the margin of superiority for the intervention. To have 95% certainty (power) that a test at 0.05 level of significance would find a statistically significant difference between the means, the study would include a minimum of 20 patients in each group.
The planned RCT The telemonitoring service will be offered to all patients admitted at UNN's Heart Polyclinic, satisfying the inclusion criteria. The study comprises an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.
Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made.
Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
The study calendar is shown below. Recruiting period: 14 months Follow-up period: 6 months Number of patients: 40
Randomization: will be performed using sequentially numbered sealed opaque envelopes
Blinding: independent outcome assessors and data analysts are blinded to which group the patient has been assigned to (patients are not blinded due to the nature of the intervention).
Challenges and opportunities Qualitative research with semi structured interviews. Patients in the intervention group and health care professionals will be asked to state their opinion of the service. The research team will also observe patients' interactions with the system after the 6 months of the study. A qualitative summary and thematic analysis of significant features of opinions and actions will be connected to best practices. The purpose is to be able to understand how best practices can be developed in the Northern Norwegian context, and describe their mechanisms. The innovation intention is to adjust the services as they develop, by considering the identified additional conditions for future development.
Ethics and privacy With recent events and advances in information technology and the Internet, confidentiality regarding handling of patient private data has become a critical aspect of a study design as privacy is a fundamental right in the public healthcare domain. In this project confidentiality of private health information will be ensured according to the Health Personnel Act § 21, helsepersonelloven § 21, and described in LOV2001-05-18 nr.24 (Helse- og omsorgsdepartementet, 2001). All private personal data will be de-identified: every unique identifying number, characteristic, or code identifiers of the individual or of relatives, employers, or household members of the individual will be removed so that the information can be used alone or in combination with other information. The resulting data will be analysed by a statistician to ensure that no individually identifiable health information remains. The consent of participants will be required by means of providing a letter of informed consent to be signed.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Telemonitoring (intervention) | Experimental | Device: Home telemonitoringan intervention arm testing the proposed telemonitoring service and a control arm with the current treatment. Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made. |
| Usual care (control) | No intervention | –Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Presence of CHF signs and symptoms such as dyspnoea and peripheral or pulmonary oedema requiring diuretic administration (New York Heart Association [NYHA] functional class II-IV); and ejection fraction (EF) under 40% combined or not with a left ventricular filling pattern supporting the presence of diastolic dysfunction, according to the American College of Cardiology/American Heart Association Guidelines for chronic heart failure.
Key exclusion criteria (2 listed)
- Severe psychiatric disturbance diagnosed by DSM-IV-TR criteria. Any disability that may prevent the subject from completing the informed consent form or other study requirements.
- Medication or drug dependency or abuse (except for nicotine). Inability to handle the technological devices included in the study, for some other reason.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Home telemonitoringAlso: Telecare, TelehealthThe intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic. | Device | Telemonitoring (intervention) |
Primary outcome
Heart failure related hospital readmissions
Time frame: Intervention period (6 months)
Calculated as the proportion of patients readmitted to hospital at least once during the period of follow-up
Additional costs/savings resulting from the service
Time frame: 6 months
Defined as the difference in the costs of medical care during the study, identified through a cost analysis, between the intervention and control arms
2 secondary outcomes
Length of stay
Time frame: 6 months
Assessment of Quality of Life
Time frame: At baseline and end of study (6 months)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2015.
Related trials for Congestive Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
J. Artur Serrano, PhD principal investigator
Senior Research Scientist, Norwegian Centre for Telemedicine, University Hospital of North Norway
Paal Tande, MD study director
Leader Cardiology Department, University Hospital of North Norway
Marina Nilsen, Nurse study chair
Leader Heart Polyclinic, University Hospital of North Norway
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Home telemonitoring in people with Congestive Heart Failure, run by University Hospital of North Norway at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact J. Artur Serrano, PhD (+4796683435, jarturserrano@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heart failure related hospital readmissions (time frame: Intervention period (6 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2015.